izpis_h1_title_alt

Low virus-specific IgG antibodies in adverse clinical course and outcome of tick-borne encephalitis
ID Bogovič, Petra (Avtor), ID Lotrič-Furlan, Stanka (Avtor), ID Avšič-Županc, Tatjana (Avtor), ID Korva, Miša (Avtor), ID Lusa, Lara (Avtor), ID Strle, Klemen (Avtor), ID Strle, Franc (Avtor)

.pdfPDF - Predstavitvena datoteka, prenos (1,02 MB)
MD5: AE14D21037EFA54A283A3AB663E45037
URLURL - Izvorni URL, za dostop obiščite https://www.mdpi.com/2076-2607/9/2/332 Povezava se odpre v novem oknu

Izvleček
Tick-borne encephalitis (TBE) is associated with a range of disease severity. The reasons for this heterogeneity are not clear. Levels of serum IgG antibodies to TBE virus (TBEV) were determined in 691 adult patients during the meningoencephalitic phase of TBE and correlated with detailed clinical and laboratory parameters during acute illness and with the presence of post-encephalitic syndrome (PES) 2–7 years after TBE. Specific IgG antibody levels ranged from below cut-off value (in 32/691 patients, 4.6%), to 896 U/mL (median = 37.3 U/mL). Patients with meningoencephalomyelitis were more often seronegative (24.3%; 9/37) than those with meningoencephalitis (4.7%; 20/428) or meningitis (1.3%; 3/226). Moreover, patients with antibody levels below cut-off had longer hospitalization (13 versus 8 days); more often required intensive care unit treatment (22% versus 8%) and artificial ventilation (71% versus 21%); and had a higher fatality rate (3/32; 9.4% versus 1/659; 0.2%) than seropositive patients. These results were confirmed when antibody levels, rather than cut-off values, were correlated with clinical parameters including the likelihood to develop PES. Low serum IgG antibody responses against TBEV at the onset of neurologic involvement are associated with a more difficult clinical course and unfavorable long-term outcome of TBE, providing a diagnostic and clinical challenge for physicians.

Jezik:Angleški jezik
Ključne besede:tick-borne encephalitis, humoral immune response, serum IgG antibodies, course, outcome
Vrsta gradiva:Članek v reviji
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:MF - Medicinska fakulteta
Status publikacije:Objavljeno
Različica publikacije:Objavljena publikacija
Leto izida:2021
Št. strani:12 str.
Številčenje:Vol. 9, iss. 2, art. 332
PID:20.500.12556/RUL-135014 Povezava se odpre v novem oknu
UDK:616.9
ISSN pri članku:2076-2607
DOI:10.3390/microorganisms9020332 Povezava se odpre v novem oknu
COBISS.SI-ID:51124995 Povezava se odpre v novem oknu
Datum objave v RUL:17.02.2022
Število ogledov:1196
Število prenosov:147
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
Objavi na:Bookmark and Share

Gradivo je del revije

Naslov:Microorganisms
Skrajšan naslov:Microorganisms
Založnik:MDPI AG
ISSN:2076-2607
COBISS.SI-ID:523277081 Povezava se odpre v novem oknu

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:07.02.2021

Projekti

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:P3-0296
Naslov:Bolezni in povzročitelji, ki jih v Sloveniji prenašajo členonožci

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:J3-1744
Naslov:Poglobljena analiza vplivov dejavnikov povzročitelja in gostitelja pri akutni in kronični lymski boreliozi

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:J3-8195
Naslov:Dejavniki povzročitelja in gostitelja, ki vplivajo na klinične znake, težo in izid lymske borelioze

Financer:Drugi - Drug financer ali več financerjev
Program financ.:Global Lyme Alliance

Financer:Drugi - Drug financer ali več financerjev
Program financ.:MGH-ECOR

Financer:NIH - National Institutes of Health
Številka projekta:R21 AI144916

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Nazaj